



Government of India
Central Drugs Standard Control Organisation (Headquarter)
(Directorate General of Health Services)
FDA Bhavan, ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail: dci@nic.in

File No. BIO/CT/20/000060

Dated 31-Mar-2021

To,

M/s Synchron Research Services Pvt. Ltd.,
Synchron House B/H Mondeal Park, Nr Gurudwara,
Ahmedabad - 380059, India

Subject: Application for grant of permission to conduct clinical trial entitled – “A Randomized, Two-Arm, Parallel group, Single dose Comparative PK and safety study comparing ADL-018 With US-Licensed Xolair administered through subcutaneous route in healthy adult subjects” vide protocol no. OMA-2020-1773, version no. 01, dated 05 May 2020 - regarding

Ref.: Your Application No. BIO/CT04/FF/2020/19854 dated 23-May-2020

Sir,

With reference to your Application No.: BIO/CT04/FF/2020/19854 dated 23-May-2020, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8;
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be;
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal;
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination;
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter;
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorised by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

Yours faithfully,

VENUGOPAL
GIRDHARILAL
SOMANI

Digitally signed by VENUGOPAL
GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS,
ou=CDSCO DGHS, postalCode=431401,
st=Maharashtra,
2.5.4.20=173003340df63d409632379e1471
bf0ae9f002ba56c83bfbb2154e39961af7,
cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2021.04.01 16:20:58 +05'30'

(Dr. V. G. Somani)
Central Licensing Authority

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR
INVESTIGATIONAL NEW DRUG

The Central Licencing Authority hereby permits M/s Synchron Research Services Pvt. Ltd., Synchron House B/H Mondeal Park, Nr Gurudwara, Ahmedabad - 380059, India to conduct clinical trial entitled – “A Randomized, Two-Arm, Parallel group, Single dose Comparative PK and safety study comparing ADL-018 With US-Licensed Xolair administered through subcutaneous route in healthy adult subjects” vide protocol no. OMA-2020-1773, version no. 01, dated 05 May 2020 of the new drug or investigational new drug in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date: 31-Mar-2021

VENUGOPAL
GIRDHARILAL
SOMANI

Digitally signed by VENUGOPAL
GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME
AFFAIRS, ou=CDSCO DGHS,
postalCode=431401, st=Maharashtra,
2.5.4.20=173603345df62d489632379a14
71bfdae9f0b2bea56c83bfbe2154e399b
1af7, cn=VENUGOPAL GIRDHARILAL
SOMANI
Date: 2021.04.01 16:23:02 +05'30'

(Dr. V. G. Somani)
Central Licensing Authority

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Omalizumab (ADL-018) (r-DNA origin)
Therapeutic class:	Monoclonal antibodies
Dosage form:	Solution for injection
Composition:	Omalizumab =150 mg/ml IH Active Lysine Hydrochloride = 36.4 mg/ml U.S.P. Inactive Polysorbate 20 =0.4 mg/ml U.S.P. Inactive L-Histidine Monohydrate =2.34 mg/ml U.S.P. Inactive L-Histidine =1.37 mg/ml U.S.P. Inactive
Indications:	<ul style="list-style-type: none"> Indicated for patients of 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. It has been shown to decrease the incidence of asthma exacerbations in these patients. Indicated for the treatment of adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1	Synchron Research Services Pvt. Ltd., Synchron House, Behind Mondeal Park, Nr. Gurudwara, SG Highway Ahmedabad Gujarat - 380059	Sangini Hospital Ethics Committee, Sangini Hospital Santorini Square, B/H Abhishree Complex Opp. Star Bazar Nr. Jodhpur Cross Roads Satellite, Ahmedabad Gujarat. EC Reg. No.: ECR/147/Inst/GJ/2013/RR-19	Dr. Rajesh Bhayani